GH Research PLC Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track
Revenue: $148 million, up 4% year-over-year on an organic basis. Non-GAAP EPS: $0.08 per share. Adjusted EBITDA Margin: 9%, representing a 400 basis point expansion year-over-year. Free Cash Flow: $2 million for the quarter. Cash Position: $530 million in cash, cash equivalents, and marketable securities. Sample Management Solutions Revenue: $81 million, up 3% year-over-year. Multiomics
What is Nasdaq Cash, Cash Equivalents, Marketable Securities? Nasdaq‘s quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 ($641.00 Mil) to Mar. 2024 ($561.00 Mil) but then increased from Mar. 2024 ($561.00 Mil) to Jun. 2024 ($590.00 Mil). Nasdaq‘s annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($601.00 Mil) to Dec. 2022
What is Altice USA Cash, Cash Equivalents, Marketable Securities? Altice USA‘s quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 (MXN5,127.21 Mil) to Mar. 2024 (MXN4,720.81 Mil) but then increased from Mar. 2024 (MXN4,720.81 Mil) to Jun. 2024 (MXN6,633.84 Mil). Altice USA‘s annual cash, cash equivalents, marketable securities increased from Dec. 2021 (MXN4,014.82 Mil)
What is Centrica Cash, Cash Equivalents, Marketable Securities? Centrica‘s quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 (€7,972.53 Mil) to Dec. 2023 (€7,828.16 Mil) but then stayed the same from Dec. 2023 (€7,828.16 Mil) to Jun. 2024 (€7,506.46 Mil). Centrica‘s annual cash, cash equivalents, marketable securities declined from Dec. 2021 (€5,442.99 Mil) to
What is Gamida Cell Cash, Cash Equivalents, Marketable Securities? Gamida Cell‘s quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($60.43 Mil) to Dec. 2023 ($46.55 Mil) but then stayed the same from Dec. 2023 ($46.55 Mil) to Mar. 2024 ($24.78 Mil). Gamida Cell‘s annual cash, cash equivalents, marketable securities declined from Dec. 2021
What is Maple Gold Mines Cash, Cash Equivalents, Marketable Securities? Maple Gold Mines‘s quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (€3.27 Mil) to Mar. 2024 (€1.83 Mil) but then increased from Mar. 2024 (€1.83 Mil) to Jun. 2024 (€3.59 Mil). Maple Gold Mines‘s annual cash, cash equivalents, marketable securities increased from Dec.
What is WiMi Hologram Cloud Cash, Cash Equivalents, Marketable Securities? WiMi Hologram Cloud‘s quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 (€82.76 Mil) to Jun. 2023 (€81.40 Mil) but then increased from Jun. 2023 (€81.40 Mil) to Dec. 2023 (€99.38 Mil). WiMi Hologram Cloud‘s annual cash, cash equivalents, marketable securities declined from Dec.
What is Cerrado Gold Cash, Cash Equivalents, Marketable Securities? Cerrado Gold‘s quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (C$15.68 Mil) to Dec. 2023 (C$0.57 Mil) but then increased from Dec. 2023 (C$0.57 Mil) to Mar. 2024 (C$9.72 Mil). Cerrado Gold‘s annual cash, cash equivalents, marketable securities increased from Dec. 2021 (C$2.25 Mil)
What is Clean Air Metals Cash, Cash Equivalents, Marketable Securities? Clean Air Metals‘s quarterly cash, cash equivalents, marketable securities declined from Oct. 2023 ($5.10 Mil) to Jan. 2024 ($4.41 Mil) but then stayed the same from Jan. 2024 ($4.41 Mil) to Apr. 2024 ($3.81 Mil). Clean Air Metals‘s annual cash, cash equivalents, marketable securities increased